 This is a single-arm, single center, phase II trial to investigate the feasibility and toxicity of FSRT plus TMZ for refractory brain metastases, which are defined as A: multiple brain metastases3 lesions; B: large brain metastaseswith one lesions volume is no smaller than 6cc or the longest diameter is no shorter than 3cm; C: meningeal metastases. 